SCHEDULE: Ayrton Capital, Alto Fund Disclose 7.87% Stake in Envoy Medical

Ayrton Capital LLC, Alto Opportunity Master Fund, SPC, and Waqas Khatri have jointly disclosed a 7.87% beneficial ownership stake in Envoy Medical, Inc. through warrants.

Summary

• Ayrton Capital LLC, Alto Opportunity Master Fund, SPC Segregated Master Portfolio B, and Waqas Khatri (collectively, the "Reporting Persons") have filed a Schedule 13G.
• The filing reports beneficial ownership of 2,457,963 shares of Envoy Medical, Inc. Class A Common Stock for each Reporting Person.
• This represents 7.87% of the company's outstanding Class A Common Stock.
• The shares are issuable upon the exercise of certain warrants held by the Reporting Persons.
• The ownership is subject to a 9.99% beneficial ownership blocker, limiting the maximum beneficial ownership.
• The percentage calculation is based on 28,786,511 shares of Common Stock outstanding as of November 21, 2025, plus the 2,457,963 shares issuable from warrants.
• The ownership position was established as of December 31, 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as it signals institutional interest and a significant investment in Envoy Medical, Inc. by established funds, which can be a positive indicator for other investors.

Positives

• The disclosure of a significant institutional stake by Ayrton Capital and Alto Opportunity Master Fund could be interpreted as a vote of confidence in Envoy Medical, Inc.'s future prospects.
• The investment through warrants suggests a potential long-term investment strategy by the Reporting Persons.

Risks

• The reported shares are issuable upon the exercise of warrants, meaning the actual common stock ownership is contingent on this exercise.
• A 9.99% beneficial ownership blocker limits the immediate voting power and influence of the Reporting Persons, preventing them from exceeding this threshold.

Future Outlook

This Schedule 13G filing is a disclosure of a past ownership position and does not contain any forward-looking statements or guidance from Envoy Medical, Inc. or the Reporting Persons regarding future performance or strategy.

Industry Context

StockSavvy.ai notes that the disclosure of a significant beneficial ownership stake by institutional investors like Ayrton Capital and Alto Opportunity Master Fund is a common occurrence in the public markets. Such filings indicate that sophisticated investors are taking positions in companies, which can sometimes be interpreted as a vote of confidence. This particular filing highlights an investment in Envoy Medical, Inc., a company operating in the medical sector, which often attracts specialized institutional funds.

Comparison to Industry Standards

• StockSavvy.ai observes that a 7.87% stake is a substantial position for an institutional investor, placing Ayrton Capital and Alto Opportunity Master Fund among the larger shareholders of Envoy Medical, Inc.
• While specific comparable companies or projects are not detailed in this filing, such a stake typically positions the investors to potentially engage with management on strategic matters, although the filing explicitly states the shares were not acquired for the purpose of changing or influencing control.
• Similar stakes are often seen in emerging growth companies where institutional investors seek to gain exposure to innovative technologies, akin to how funds might invest in early-stage biotech firms or medical device startups like Inari Medical or Shockwave Medical, where significant institutional backing is common.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake could potentially increase investor confidence and liquidity.
• Company Management: The presence of a large institutional investor may lead to increased scrutiny or engagement, though the filing states the investment is not for control purposes.

Key Dates

Recommendation

While the disclosure of a significant institutional stake is generally positive, a Schedule 13G filing primarily reports a past event and does not provide new operational or financial performance data. The investment via warrants suggests a long-term view, but without further context on Envoy Medical's fundamentals or strategic direction, a 'hold' recommendation is prudent for existing investors, while potential new investors should conduct further due diligence.

Keywords

Envoy Medical, Ayrton Capital, Alto Opportunity Master Fund, Waqas Khatri, beneficial ownership, warrants, institutional investor, common stock, Schedule 13G